INDV

Business Context and Reporting Period

Company: Indivior PLC (trading as Indivior Pharmaceuticals, Inc. on Nasdaq under symbol INDV)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Indivior is a pharmaceutical company focused on treating opioid use disorder (OUD). Its primary revenue driver is SUBLOCADE, a buprenorphine-based injectable, alongside sublingual products like SUBOXONE. The company operates as a single segment and recently cancelled its London Stock Exchange listing to trade exclusively on Nasdaq.

Key Financial Metrics

Note: Debt consists of $18 million current and $304 million long-term. Cash and investments total $473 million as of September 30, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Q3 2025 revenue increased 2% ($7 million) year-over-year, driven by a 14% increase in U.S. SUBLOCADE sales ($203 million). This offset declines in legacy sublingual products and OPVEE.
• Profitability Improvement: The company returned to profitability with $42 million net income in Q3 2025, compared to $22 million in Q3 2024. The nine-month period showed a significant turnaround from a $14 million loss in 2024 to a $108 million profit in 2025.
• Expense Reductions: Total operating expenses decreased 9% in Q3 2025 compared to Q3 2024, primarily due to the absence of a $36 million litigation settlement expense recorded in the prior year.
• Restructuring Costs: Q3 2025 included $72 million in restructuring and impairment charges, including $37 million related to the discontinuation of OPVEE sales support and $35 million for corporate transition initiatives.
• Cash Flow: Operating cash flow for the nine months ended September 30, 2025, surged to $194 million from $53 million in the prior year period.

Guidance, Outlook, and Risks

• Strategic Shifts: In October 2025, the company announced plans to exit several non-U.S. markets (including the U.K., Ireland, and Italy) to optimize the Rest of World (ROW) business. This is expected to result in $30 million to $50 million in charges, mostly recognized in Q4 2025 and Q1 2026.
• Product Strategy: Sales and marketing support for OPVEE was discontinued in Q3 2025, though distribution will continue upon request. The company is refocusing its R&D pipeline on Phase 2 OUD assets (INDV-2000 and INDV-6001).
• Litigation: The company has accrued $80 million for a settlement covering certain civil opioid litigation (Opioid MDL). The opt-in process for subdivisions is expected to conclude by January 2026. Private plaintiff cases and dental injury claims remain ongoing with no estimated loss.
• Tax Matters: A $32 million tax expense was recorded in 2025 related to a probable settlement with U.K. HMRC regarding prior intercompany financing. This is a one-time item.
• Liquidity: The company maintains negative working capital due to the timing of rebate payments versus collections but believes cash, investments, and operating cash flow are sufficient to meet obligations for at least 12 months.

Investor Verification Checklist

• Restructuring Impact: Verify the timing and magnitude of the $30–$50 million charges associated with the ROW market exits announced in October 2025.
• OPVEE Discontinuation: Confirm the full extent of inventory write-downs and contract termination costs related to the cessation of OPVEE marketing support.
• Litigation Settlements: Monitor the progress of the Opioid MDL opt-in process and the potential for additional liabilities from private plaintiff or dental injury lawsuits not covered by current accruals.
• Tax Settlement: Review the finalization of the U.K. HMRC settlement and its impact on future effective tax rates.
• Financial Revisions: Note that prior period financial statements (2022–2024) were revised to correct an overstatement of the U.S. Branded Fee accrual; ensure comparisons use the revised figures.